Literature DB >> 29446705

Prospective Assessment of Rhinovirus Symptoms and Species Recurrence in Children With and Without an Acute Wheezing Exacerbation.

Robert Lethbridge1, Franciska Prastanti1, Cassandra Robertson1, Stephen Oo1, Siew-Kim Khoo1, Peter N Le Souëf1, Ingrid A Laing1.   

Abstract

To assess if the difference in species-specific immune response to RV-C correlates with a higher frequency of reinfection, shorter time to reinfection, or different symptom severity than infections with RV-A or RV-B. Forty-three patients were enrolled of which 34 were successfully tracked longitudinally over 3 months, with nasal swabs and symptom questionnaires provided every 2 weeks to identify rhinovirus (RV) strains and the concurrent symptomatology. No difference was found in the time to reinfection with an RV species between RV-C and RV-A or RV-B (p = 0.866). There was a trend toward more rapid reinfection with the same species in RV-C than RV-A (55.1 days vs. 67.9 days), but this failed to reach statistical significance (p = 0.105). RV infections were generally associated with only minor symptoms, with rhinorrhea being the only significantly associated symptom (p = 0.01). RV-C was shown to have higher levels of lethargy and wheeze than other RV species. Time to reinfection with subsequent RV is not influenced by the species of the preceding RV.

Entities:  

Keywords:  Picornaviridae; children; immunoglobulin; respiratory tract infection; rhinovirus c; wheeze

Mesh:

Year:  2018        PMID: 29446705     DOI: 10.1089/vim.2017.0152

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  1 in total

1.  Rhinovirus C15 Induces Airway Hyperresponsiveness via Calcium Mobilization in Airway Smooth Muscle.

Authors:  Vishal Parikh; Jacqueline Scala; Riva Patel; Corinne Corbi; Dennis Lo; Yury A Bochkov; Joshua L Kennedy; Richard C Kurten; Stephen B Liggett; James E Gern; Cynthia J Koziol-White
Journal:  Am J Respir Cell Mol Biol       Date:  2020-03       Impact factor: 6.914

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.